NASDAQ:PCRX
Pacira BioSciences, Inc.
Pacira BioSciences, Inc.'s revenue grew 3.6% in fiscal 2025 to $726.4M while operating margin rose to 2.6%. Free cash flow was $136.7M, 18.8% of revenue, and the diluted share count fell 2.6%.Summary generated from Pacira BioSciences, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$726.4M
Revenue growth+3.6%
Revenue, 5-yr CAGR+11.1%
Gross margin79.4%
Operating margin2.6%
Net margin1.0%
ROIC1.0%
Return on equity1.0%
Debt / equity0.54
Free cash flow$136.7M
FCF margin18.8%
Share count change−2.6%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 542 | 667 | 675 | 701 | 726 |
| Operating income | 90 | 60 | 88 | −73 | 19 |
| Net income | 42 | 16 | 42 | −100 | 7 |
| Free cash flow | 80 | 115 | 139 | 179 | 137 |
Recent filings
- 4Insider transaction report
Oct 9, 2026 - 8-KEntry into a material agreement
Oct 8, 2026 - 4Insider transaction report
Aug 18, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 4, 2026 - 8-KResults of operations and financial condition
Aug 4, 2026 - 8-KEntry into a material agreement
Jun 30, 2026 - 8-KDirector or officer change
Jun 11, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
Apr 30, 2026